^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lorigerlimab (MGD019)

    i
    Other names: MGD019, MGD 019, MGD-019
    Associations

    News

    Trials
    Company:
    MacroGenics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=20 --> 0 | Trial completion date: Sep 2032 --> Jan 2026 | Initiation date: Apr 2026 --> Oct 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2030 --> Jan 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • pMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    6d
    A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Dec 2032 --> Jan 2026 | Initiation date: Feb 2026 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2030 --> Jan 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • pMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    16d
    Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients. (PubMed, J Cutan Pathol)
    The eruption was refractory to treatment, despite the patient withholding lorigerlimab, leading to complete discontinuation of lorigerlimab. This report highlights the importance of histopathologic evaluation in guiding treatment decisions for lorigerlimab-associated irAEs and underscores the need for further research into its dermatologic irAEs.
    Journal • Adverse events • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    lorigerlimab (MGD019)
    3ms
    Phase II Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • pMMR
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    4ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    5ms
    Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • pMMR
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    6ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, MacroGenics | N=278 --> 32
    Enrollment change • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    7ms
    Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    8ms
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=60, Recruiting, MacroGenics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lorigerlimab (MGD019)
    8ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=278, Active, not recruiting, MacroGenics | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    11ms
    MGD019 DART® Protein in Unresectable/Metastatic Cancer (clinicaltrials.gov)
    P1, N=162, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    lorigerlimab (MGD019)
    1year
    LORIKEET: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=154, Active, not recruiting, MacroGenics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    docetaxel • prednisone • lorigerlimab (MGD019)